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Abstract: Parkin belongs to a class of multiple RING domain proteins designated as RBR (RING, in between RING, 
RING) proteins. In this review we examine what is known regarding the structure/function relationship of the Parkin 
protein. Parkin contains three RING domains plus a ubiquitin-like domain and an in-between-RING (IBR) domain. RING 
domains are rich in cysteine amino acids that act as ligands to bind zinc ions. RING domains may interact with DNA or 
with other proteins and perform a wide range of functions. Some function as E3 ubiquitin ligases, participating in 
attachment of ubiquitin chains to signal proteasome degradation; however, ubiquitin may be attached for purposes other 
than proteasome degradation.  
It was determined that the C-terminal most RING, RING2, is essential for Parkin to function as an E3 ubiquitin ligase and 
a number of substrates have been identified. However, Parkin also participates in a number of other fiunctions, such as 
DNA repair, microtubule stabilization, and formation of aggresomes. Some functions, such as participation in a multi-
protein complex implicated in NMDA activity at the post synaptic density, do not require ubiquitination of substrate 
molecules. Recent observations of RING proteins suggest their function may be regulated by zinc ion binding. We have 
modeled the three RING domains of Parkin and have identified a new set of RING2 ligands. This set allows for binding of 
two rather than just one zinc ion, opening the possibility that the number of zinc ions bound acts as a molecular switch to 
modulate Parkin function. 
Keywords: Parkin, zinc-binding, RING, domains, E3 ligase ubiquitination. 
1. INTRODUCTION 
 Genetic mutations in six genes have been implicated in 
hereditary Parkinson’s disease (PD). Mutations in any one of 
three genes, -synuclein, leucine-rich repeat kinase 2 
(LRRK2), or ATP13A2, give rise to autosomal dominant 
PD, whereas autosomal recessive PD occurs from mutations 
in PINK1 [PTEN (phosphatase and tensin homologue 
deleted on chromosome 10)-induced putative kinase 1], DJ-
1, or the Parkin gene (reviewed in [1-3]). First identified in 
Japan, Autosomal Recessive Juvenile Parkinson’s disease 
(ARJP) has an early onset and results from mutations in the 
Parkin gene [4, 5]. Symptoms of ARJP resemble those of 
idiopathic PD although Lewy bodies, the diagnostic hallmark 
of PD, are absent in ARJP. Most studies of the Parkin 
protein have focused on its role in Parkinson’s disease; 
however, studies have also shown that Parkin participates in 
the clearance of the amyloidogenic Alzheimer’s disease  
A (1-42) peptide [6-8] and in the clearance of the 
Huntington’s disease polyglutamine proteins [9, 10]. Parkin 
binding and ubiquitination of polyglutamine proteins is 
enhanced by hsp70 interaction with Parkin [9]. Both A (1-42) 
and polyglutamine proteins impair proteasomal function, a 
common characteristic feature of several adult neurodegen-
erative diseases, emphasizing the importance of Parkin 
activity in maintaining the cellular ubiquitin proteasome 
system.  
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 The Parkin gene is located on chromosome 6 (6q25.2-
q27), is greater than 500 kb and contains 12 exons [4]. The 
Parkin gene coding sequence is in the GenBank database 
(accession number AB009973) and contains the nucleic acid 
base pair and protein amino acid residue numbering of 
Kitada, et al. [4]. The 4.5 kb parkin transcript contains a 
1395 bp open reading frame that is translated into a 465 
amino acid protein with a molecular weight of 51,652 
daltons. Parkin is abundantly expressed in numerous parts of 
the brain as well as in heart and skeletal muscle, testis, 
stomach, adrenal gland, thyroid, and spinal chord [4].  
 The main focus of this review is to examine what is 
known regarding the structure/function relationship of the 
Parkin protein. By incorporating recent new information 
along with predicted Parkin protein structures, we hope to 
advance our understanding of how Parkin might function to 
alleviate toxicity of misfolded/aggregated proteins in PD and 
also in Alzheimer’s and Huntington’s diseases.  
II. PARKIN DOMAIN STRUCTURE 
 Parkin belongs to the E3 ubiquitin ligase subset of the 
RBR protein family (reviewed in Eisenhaber et al. (2007) 
[11]. The primary domain structure of RBR ubiquitin ligases 
consists of three consecutive domains, each of approximately 
50 amino acids: RING1, in between RING (IBR), and 
RING2. The Parkin RBR domain structure is shown in Fig. 
(1A). Historically, “RING”, an abbreviation for “Really 
Interesting New Gene”, was coined by Lovering et al. [12] 
and described a cysteine-rich motif. The combination of two 
linked RINGs in the same protein was first described by Van 
der Reijden (1999) [13] and eventually became known as the 
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Fig. (1). A) Domain Structure of the Parkin Protein. The five major domains of Parkin are listed across the top and include the Ubiquitin-like 
domain (Ubl), RING0, as well as RING1, the In Between RING domain (IBR), and RING2 within the Ring IBR RING, (RBR) region. Listed 
under each zinc binding domain is the pattern of each zinc ion binding site, i.e. RING0 site I = 4 Cys residues (C4), RING0 site II = three Cys 
and one His residue (C3H), etc. And, finally, the number of amino acid residues in each domain is listed at the bottom. Note that the RING2 
pattern of Cys and His zinc binding ligands, as well as the domain boundaries listed at the bottom are according to the Morett and Bork 
(1999) [104] selection of ligands and not those predicted by our new RING2 model. B) The spacing of Cys and His zinc ion ligands in RBR 
proteins according to an alignment comparison by Marin and Ferrus (2002) [14]. X indicates the number of amino acid residues between 
consecutive ligands in the primary protein sequence. C) The classical cross-brace structure shows the interleaved ligand arrangement for the 
two zinc binding sites and is found in many RING domains. RING1 of Parkin likely forms a cross brace structure with parkin C238=C1, 
C241=C2, C253=C3, H257, C260=C4, C263=C5, C289=C6, and C293=C7. 
RBR. The RBR structure is apparently an ancient 
evolutionary feature that has endured for over a billion years 
[14]. Parkin orthologs, genes similar to Parkin because they 
originate from a common ancestor, can be found in 
vertebrates, insects and nematodes, but not in fungi or plants 
[14]. The amino acid residues, cysteine and histidine are 
interspersed among the RING amino acid sequences in a 
pattern that promotes binding of zinc ions. A sequence 
alignment comparison of RBR proteins revealed that the two 
RING domains in the RBR differed in spacing and number 
of conserved amino acid residues [14] (Fig. 1B). In general, 
RING1 is longer with more variability in spacing than 
RING2. The Parkin RINGs can be fit into this general 
sequence structure (Fig. 1A and B). RING1 holds two zinc 
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ions in a cross brace arrangement with the first and second 
Cys pairing with the fourth and fifth Cys to hold one zinc ion 
(Fig. 1C). A second zinc ion is bound by the third Cys, the 
His, and paired with the sixth and seventh Cys, (reviewed in 
Borden (2000) [15] and Matthews and Sunde (2002) [16]).  
 The arrangement of conserved Cys and His amino acid 
residues in the IBR (the domain separating RING1 from 
RING2, see Fig. 1A) is split between two zinc-binding 
domains, one site containing four Cys (in Parkin, C332, 
C337, C352 and C360) and the other containing three Cys 
and one His (C365, C368, H373 and C377) [17]. The IBR 
domain structure of Parkin was determined using NMR 
spectroscopy and the zinc binding arrangement brings the N- 
and C-terminus of the IBR domain together with the result 
that RING1 and RING2 are brought into close proximity 
[17].  
 The structural determination of RING2 was problematic, 
leaving several unresolved issues. For example, a RING2 
domain structural study of the closely related HHARI protein 
showed that only one zinc ion was bound and by analogy 
this was projected to Parkin RING2 [18]. However, in a 
Parkin zinc depletion experiment where zinc ions were 
sequentially removed by addition of dilute formic acid to 
denature Parkin, it was found that the total number of zinc 
ions bound by Parkin required that RING2 bind two zinc 
ions [19]. This, as well as other inconsistencies will be 
addressed in “Part VIII. Predicted RING structures”. 
 Recently a third RING domain was identified in Parkin 
and, as it is located upstream of RING1, was named RING0 
[19] (Fig. 1A). The RING0 structural domain was identified 
by classic proteolytic biochemistry which is based on the 
premise that a stable, folded conformation limits proteolysis. 
A sequence comparison of human Parkin with Parkin of 12 
other species showed a high degree of conservation through 
the RING0 domain and indicated the conserved Cys residues 
that are most likely involved in zinc binding [19]. RING0 
apparently has two parts (C4 and C3H) separated by a 26 
amino acid linker region (Fig. 1A and B). HOIL-1 is the only 
other RBR protein to contain a zinc binding motif upstream 
of RING1, however, it appears to bind only one zinc ion 
(discussed in Hristova et al. (2009) [19]. RING0 will also be 
discussed in more detail in “Part VIII: Predicted RING 
structures”. 
 Parkin contains 35 cysteines and binds a total of eight 
zinc ions, apparently two each in RING0, RING1, the IBR, 
and RING2 [19]. There are considered to be three reasons for 
proteins to bind zinc, structural, catalytic, and cocatalytic 
(reviewed in Auld (2001)) [20]. There is evidence that zinc 
binding directly affects Parkin structure both in regards to 
stability and for proper folding. Structural zinc sites contain 
4 amino acids whose R groups can donate a pair of electrons 
for Zn
++ 
binding. The amino acid Cys is the preferred 
electron donor with His as the second most prevalent donor.  
 In light of this, it is not surprising that the IBR domain of 
Parkin is completely unfolded by removal of zinc ions with 
EDTA [17], as is RING2 of the HHARI protein [18]. As zinc 
ions were removed by equivalents of EDTA the CD spectra 
of full length Parkin showed a gradual loss of secondary 
structure, i.e., -helical or -sheet [19]. However, it should 
be noted that removal of zinc by EDTA does not completely 
denature the protein; therefore, not all Parkin structure is 
dependent on binding of zinc ions [19]. Structural zinc 
binding can exert indirect effects on catalytic function of the 
protein by changing the chemical environment of the active 
catalytic site or by realigning important amino acids in that 
site [20]. In addition, certain Parkin mutations that disrupt 
zinc binding sites may also destroy E3 ubiquitin ligase 
activity by affecting the stability or solubility of Parkin [21]. 
 One other Parkin domain, the ubiqitin-like domain (Ubl) 
located at the N-terminus, does not appear to be involved in 
zinc binding. The crystal structure of the Parkin Ubl shows a 
typical ubiquitin fold, containing 5 -sheets and two -
helices,  [22]. From analysis of ARJP mutations in 
this domain it has been determined that the domain is 
stabilized both by hydrogen bonds and hydrophobic 
interactions [22]. One mutation, R42P, causes a change in 
the position of the 3 strand and completely unfolds the Ubl 
domain [22, 23]. Of interest is the discovery of an N-
terminally truncated 42 kDa Parkin protein that is formed 
from an internal methionine start site (amino acid 80) [24]. 
This N-terminally truncated Parkin which lacks the Ubl 
domain was stable [24] suggesting that lack of the Ubl 
domain does not necessarily induce degradation of Parkin.  
III. PARKIN MUTATIONS 
  Numerous naturally occurring Parkin mutations have 
been discovered and many of these are pathological, 
resulting in ARJP [4, 5]. The number of mutations, the 
location of the mutation and whether the mutation was 
heterozygous, all influence clinical manifestations [25]. An 
excellent ARJP mutational analysis was performed by 
Sriram et al. in which the characteristics of 12 ARJP 
mutations were determined in regards to substrate binding 
and E3 ligase activity [26]. Mutations have also been 
engineered so as to better understand how Parkin structure 
might affect Parkin function [27, 28].  
C-Terminal Mutations Affect Parkin Stability 
 Parkin is aggregation-prone and is dependent on 
chaperones for proper folding [29]. A series of engineered 
deletion mutations involving the 16 C-terminal amino acids 
showed that truncations exceeding 3 amino acids produced 
insoluble Parkin [29]. An ARJP mutation in which 
tryptophan 453 is replaced with a termination codon 
(W453X), lacks the last 13 amino acids and is insoluble; 
however, the chaperone, hsp70, which prevents aggregation 
of wild type Parkin also promotes folding of the W453X 
protein [29]. Using proteinase K digestion, it was found that 
the conformation assumed by W453X is different from that 
of wild type Parkin [29].  
 The insolubility of C-terminal deletions is specific to 
Parkin and is not shared by the very similar HHARI [30]. 
Nor do the C-terminal amino acids from HHARI rescue a 
hybrid Parkin-HHARI construct as the chimeric protein was 
rapidly degraded by the proteasome [30]. In Parkin, the 
amino acid F463 was found to be highly conserved between 
species, and when mutated to Ala, was found to form 
insoluble aggregates [30]. The role of the C-terminus in 
Parkin stability will be addressed in further detail in “Part 
VIII. Predicted RING structures”. 
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N-Terminal Mutations 
 The mutation R42P is located in the ubiquitin-like 
domain and is often mentioned in the literature. It appears 
that R42P protein is highly unstable, being rapidly degraded 
by the proteasome. Only under conditions of proteasome 
inhibition, can R42P be detected and then it is found in the 
insoluble fraction. This suggests that R42P protein assumes a 
non-native conformation which is rapidly degraded [30]. 
Interestingly, an N-terminally truncated variant of Parkin 
found in human brain and cultured cells that resulted from 
translation initiation at an internal methionine residue at 
position 80 [24] was soluble whereas full length Parkin 
carrying the R42P mutation was not [27].  
Mutation of Parkin Cysteine Residues 
 Since 28 of the 35 cysteines in Parkin are involved in 
zinc binding, it was of interest to determine what would 
happen if any of those cysteines were mutated. Mutational 
analyses revealed that the great majority of the Parkin Cys 
residues are essential to maintaining Parkin solubility [21, 
27]. Cysteine mutations that did not appear to affect 
solubility were C59A, C95A, C268A, C323A, C431A and 
C451A [21].  
 Finally, there are two interesting experimental outcomes 
regarding mutations. In one experiment, a double mutation 
(R42P and W453X) was expressed in the same protein. The 
R42P alone resulted in proteasomal degradation of Parkin, 
i.e., instability, whereas the W453X mutation alone resulted 
in insoluble aggregates. On expression in SH-SY5Y cells, 
the double mutant Parkin was only detected with proteasome 
inhibition, and then only in insoluble aggregates. Therefore, 
proteasomal degradation was dominant over aggregation, 
i.e., no aggregates formed with an intact ubiquitin 
proteasome degradation system [30]. The second interesting 
experimental outcome revealed that some innocuously 
appearing mutations, i.e., ones showing no signs of 
decreased Parkin solubility, sensitized Parkin to cell-induced 
stress [31]. That stress might include oxidative stress, 
proteolytic (unfolded protein) stress, s-nitrosylation, and/or 
neurotoxins. Wang et al. (2005) [31] then summarized the 
types of mutations according to their effects on Parkin, the 
first type by directly reducing or destroying catalytic 
function, the second type by changing solubility and 
location, and the third type by increasing sensitivity to 
environmental stresses.  
IV. PARKIN FUNCTIONS IN CELLULAR PROTEIN 
REMOVAL 
 Parkin functions as a top level manager in the cell’s 
Sanitation Department. The ubiquitin proteasome system 
(UPS) is the main cellular protein removal system (reviewed 
in Finley and Chau (1991) [32]); however, should the UPS 
become overwhelmed or in some way incapacitated, proteins 
to be removed may be sequestered in aggresomes for 
eventual autophagic clearance (reviewed in Johnston et al. 
(1998), Kopito (2000) [33, 34]).  
Parkin and the Ubiquitin Proteasome System 
 In the UPS a small protein tag, ubiquitin, is covalently 
attached to the target protein through a series of steps, the 
last catalyzed by an E3 ubiquitin ligase. The first step is the 
ATP-dependent activation of ubiquitin by an E1 ubiquitin-
activating enzyme. The activated ubiquitin is then transferred 
to a ubiquitin-conjugating enzyme, E2. The E3 ubiquitin 
ligase binds both the E2-ubiquitin and a specific protein 
target to which the ubiquitin is then covalently attached. 
Each step in the process becomes more restricted in its 
substrate, with the E3 ligase being the most specific 
(reviewed in Finley and Chau (1991) [32]; more recently in 
Deshaies and Joazeiro (2009) [35]). Parkin has been shown 
to have E3 ubiquitin ligase activity [36-39]. Consistent with 
a role in the ubiquitin proteasome system, Parkin has been 
shown to bind two subunits in the 26S proteasome, Rpn10 of 
the 19S regulatory subcomplex and the 4 subunit of the 20S 
proteolytic core [40, 41]. 
 Ubiquitin is attached by formation of an isopeptide bond 
between the ubiquitin C-terminal Gly residue and the -
amino group of a Lys residue in the targeted protein. There 
are at least three ways for a protein to be ubiquitinated: i) a 
chain of ubiquitin molecules formed by linkage to Lys 48 of 
the previously attached ubiquitin, ii) a chain of ubiquitin 
molecules linked through ubiquitin Lys 63, and iii) 
multimonoubiquitination, defined as multiple ubiquitin 
molecules per protein but attachment is one ubiquitin per 
lysine residue. Ubiquitin chains formed by Lys 48 linkage 
targets proteins for proteasomal degradation and a chain of at 
least four subunits is required for recognition and 
degradation [42]. Parkin can auto-ubiquitinate and in cell-
free in vitro assays has been shown to multimonoubiquitinate 
itself [27, 43] as well as proteins that are in close proximity 
[43]. However, as discussed in the Hampe et al. report [27], 
the cell-free in vitro ubiquitination assays did not include 
other proteins that might be present in the cell. It was 
hypothesized that Parkin alone produces 
multimonoubiquitinated substrates whereas Parkin 
associated with other proteins conjugates polyubiquitin 
chains [27]. One of these other proteins may be an E4, 
(identified and described by Koegl et al. (1999) [44]. E4 
ubiquitin ligases can be described as ubiquitin chain 
elongation factors. Without E4, substrate ubiquitination 
consists of only a few ubiquitin molecules, insufficient to 
accomplish proteasomal degradation [44]. Proteins such as 
Parkin, with ubiquitin-like domains at their N-terminus, are 
analogous to substrates of E4, (in particular of UFD2, a yeast 
member of the E4 family), and are likely to be degraded by 
the proteasome system [44].  
 Parkin has been shown to be auto-ubiquitinated when 
over-expressed in cultured 293, 293T and COS1 cells [36]; 
and co-transfection with the K48R ubiquitin mutation that 
prevents formation of K48- linked chains, inhibited Parkin 
ubiquitination [36]. This suggested that the ubiquitins were 
attached as Lys 48-linked chains. An unidentified 
mammalian E4 may facilitate K48-linked chains in cultured 
cells, but with no E4 in cell-free assays, Parkin is 
multimonoubiquitinated. Another study utilizing SH-SY5Y 
cells found that ubiquitinated Parkin could be identified only 
when cells were treated with the proteasome inhibitor 
MG132, suggesting that in neuronal cells with uninhibited 
proteasomes, ubiquitinated Parkin was rapidly degraded via 
the UPS [37].  
 As mentioned above, should the ubiquitin proteasome 
system become compromised in some way, proteins to be 
Parkin Protein, Past and Future Structure/Function Research The Open Biochemistry Journal, 2011, Volume 5    13 
removed may be sequestered in the aggresome for eventual 
removal by macroautophagy. An aggresome is defined as a 
microtubule-dependent inclusion body that forms around the 
microtubule organizing center and is near to, or encompasses 
the centrosomes [33]. Proteins to be degraded by the 
aggresome pathway are actively transported along 
microtubules to the centrosome. At the same time, 
components of the UPS, e.g. ubiquitin, ubiquitin conjugating 
enzymes, proteasomal constituents, certain chaperones, and 
mitochondria are also recruited. These components are then 
organized into an aggresome (reviewed in Olanow (2004) 
[45]). Abnormal or damaged proteins are held within the 
aggresome by a cage of intermediate filaments, e.g. vimentin 
[33]. Parkin is actively involved in both the UPS and the 
aggresome system.  
Parkin Substrates Ubiquitinated for Degradation 
 Of the many responsibilities assigned to the cellular 
Sanitation Department, Parkin participates either directly or 
by “committee” (as a member of a multi-protein complex) in 
removing i) short-lived proteins, ii) altered proteins, iii) 
excessive levels of proteins and iv) unfolded proteins. A 
short-lived Parkin substrate, SIM2, is a transcription factor 
located in the nucleus, and, like many short-lived proteins, 
contains a PEST degradation signal rich in the amino acids 
proline (P), glutamic acid (E), serine (S) and threonine (T). 
The human SIM2 protein is ubiquitinated by both Parkin and 
HHARI [46]. SIM2 is located in the nucleus whereas Parkin 
is found mainly in the cytoplasm [46]; however, the authors 
note that a very small amount of Parkin can be found in the 
nucleus and this nuclear Parkin is suspected of ubiquitinating 
SIM2 [46]. 
 Sp22, a glycosylated form of -synuclein, is an altered 
protein that is ubiquitinated by Parkin [47]. Sp22 
accumulates in ARJP brain, but is undetectable in extracts 
from normal brain [47]. Sp22 appears to be unique to 
human brain as it could not be detected in lysates from 
HEK293 or SH-SY5Y cells transiently transfected with 
Parkin and -synuclein, even when those cells were 
oxidatively stressed [48].  
 The toxicity of a third class of Parkin substrates, proteins 
that exceed certain concentration levels, was demonstrated 
by exogenous overexpression of these Parkin substrates in 
cell culture. Pael-R, p38, and Synaptotagmin XI are in this 
class of Parkin substrates. Pael-R is a G protein-coupled 
receptor thought to play a role in dopaminergic signaling. 
Over-expression of Pael-R produced insoluble, ubiquitinated 
protein and increased cell death [49]. Normal expression 
levels of Pael-R do not lead to insoluble accumulations in 
brain; however, insoluble Pael-R accumulates in ARJP brain 
[49]. Recently, a rat model of PD was developed by 
capitalizing on the fact that dopaminergic nerurons are 
especially sensitive to Pael-R accumulation [50].  
 The protein p38 is a structural component of the 
aminoacyl-tRNA synthetase complex involved in protein 
biosynthesis [51]. Over-expression of p38 in the 
dopaminergic cell line SH-SY5Y increased cell death by 
approximately 6-fold whereas over-expression of both p38 
and Parkin reduced the amount of cell death when compared 
to p38 alone. This suggests that the toxic affect of increased 
p38 expression is partly alleviated by Parkin [51]. We 
assigned Synaptotagmin XI (SytXI), involved in the 
maintenance of synaptic function, to this category since a 
scan for SytXI mutations that might potentially produce 
disease in either inherited or sporadic PD was negative [52]. 
This suggested that protein levels rather than protein 
abnormalities were the key trigger for ubiquitination and 
degradation. However, this does not preclude SytXI 
degradation as a result of misfolding. In sporadic PD, SytXI 
is found in the core of Lewy bodies, suggesting that SytXI 
may be misfolded and targeted for degradation by the 
aggresome rather than by the proteasome pathway (discussed 
below). SytXI was identified as a Parkin substrate by yeast 
two hybrid followed by co-immunoprecipitation assays [53]. 
It was determined from the appearance of the bands on 
immunoblots that SytXI is polyubiquitinated and pulse-chase 
experiments using transiently transfected HEK293 cells 
showed that Parkin was responsible for the rapid turnover of 
SytXI.  
 Improperly folded proteins consititute a large number of 
proteins tagged for degradation. Upwards of 30% of newly 
synthesized proteins are improperly folded and the 
remaining 70% may at some later time be damaged or 
denatured during metabolic processes or by a change in the 
microenvironment of the cell (reviewed in Tanaka et al. 
(2004) [54]). Secretory proteins are folded within the ER; 
however, when the folding process fails, the unfolded 
proteins are removed to the cytosol for proteasomal 
degradation. Unfolded proteins produce “unfolded protein 
stress” which initiates a cellular “unfolded protein response”. 
One of the first steps in the unfolded protein response is an 
up-regulation of genes/proteins which aid in refolding or in 
protein degradation. One of these up-regulated genes, BiP, 
has become a marker for the unfolded protein response and 
was identified in the insoluble fractions of ARJP brain [49]. 
This suggests that the unfolded protein degradation pathway 
is activated in the absence of functional Parkin. An 
overwhelmed or impaired proteasomal system can also 
produce unfolded protein stress and the resulting unfolded 
protein response.  
Parkin Activity in Response to Unfolded Protein Stress is 
Cell-Specific 
 Imai et al. (2000) [36] reported that Parkin specifically 
blocked cell death from unfolded protein stress and that 
Parkin activity was cell specific, i.e., the SH-SY5Y 
dopaminergic cell line had higher levels of protein 
ubiquitination than the HEK293 human embryonic kidney 
cell line. Parkin expression was up-regulated and cell death 
resulting from unfolded protein stress was reduced [36]. 
Although West et al. (2003) [55] were unable to confirm 
these results, a study utilizing primary cultures of rat 
hippocampal neurons and astrocytes showed that Parkin 
expression increased in the astrocyte, but not in the 
hippocampal cultures in response to unfolded protein stress 
[56]. Further, treatment of astrocytes with unfolded protein 
stress inducers resulted in formation of structures similar to 
aggresomes in appearance and location [56]. 
The “Lewy Body is a Failed Aggresome” Hypothesis 
 Lewy bodies are cytoplasmic inclusions that are found in 
sporadic PD (described in Olanow et al. (2004)) [45]. They 
are very similar to aggresomes, which form in response to 
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unfolded protein stress or to an inefficient or inhibited 
proteasomal system (reviewed in Kopito (2000) [34]). 
Clearance of aggresomes may involve the macroautophagy 
system whereby the aggresome is engulfed by a double 
membrane to form an autophagasome which fuses with an 
endosome (or lysosome) to complete proteolytic digestion 
and clear the aggresome from the cell [34]. If aggresomal 
protein is not degraded, the structure may become an 
insoluble cellular inclusion. Due to the structural similarities 
between aggresomes and Lewy bodies, Olanow et al. 2004 
hypothesized that Lewy bodies are failed aggresomes, i.e. 
they are unable to complete proteolysis successfully.  
 Recently, Wong et al. (2008) [57], presented evidence 
suggesting that aggresome clearance by macroautophagy is 
determined by the components recruited to the aggresome 
along with the aggregated protein. Some proteins, such as 
the Parkin substrate p38 fail to recruit key macroautophagy 
components to the aggresome and are therefore autophagy 
resistant [57].  
Parkin Contributes to Lewy Body Formation 
 Synphilin-1 is an -synuclein interacting protein found in 
Lewy bodies [48] and confirmation of Synphilin-1 as a 
binding partner and substrate of Parkin led to the finding that 
E3 ligase activity of Parkin contributes to Lewy body 
formation. Lewy bodies are by definition, ubiquitinated 
cytoplasmic inclusions. Co-expression of Parkin, synphilin-1 
and -synuclein resulted in ubiquitinated Lewy-body-like 
inclusions [48]. However, without expression of Parkin, 
these inclusions were not ubiquitinated and therefore by 
definition were not Lewy bodies. That Parkin contributes to 
Lewy body formation was further supported by the finding 
that Parkin localized to Lewy bodies [58] and that 90% of 
nigral Lewy bodies are immunopositive for Parkin [59]. 
Parkin mutations that result in loss of Parkin ubiquitination 
activity or that result in Parkin misfolding and subsequent 
degradation would obviously prevent Lewy body formation, 
thereby providing an explanation for the absence of Lewy 
bodies in ARJP. 
Proteasome Inhibition and Aggresome Formation 
 It is important to keep in mind that most of the Parkin E3 
ligase activity assays were performed in cultured cells and 
therefore much of the ubiquitinated substrate would be 
rapidly cleared by the UPS before samples could be 
collected. Detection could occur only if the amount of 
substrate completely overwhelmed the cellular UPS or if the 
UPS were inhibited. At this point it is unclear whether 
formation of aggresomes occured in response to an 
experimentally inhibited UPS or to a “normal” clearing 
process for that particular substrate. Two factors may help to 
clarify the issue: i) is the substrate found in Lewy bodies in 
idiopathic PD?, and ii) is the protein substrate membrane-
associated?. Transmembrane or membrane-associated 
proteins are more likely to be misfolded and removed via the 
aggresome degradation system [33]. Parkin substrates 
synphilin-1, p38, and synaptotagmin XI are found in Lewy 
bodies whereas CDCrel-1 and Pael-R are examples of 
membrane-associated proteins. 
Membrane-Associated Parkin Substrates 
 CDCrel-1 is a member of the human septin protein 
family and is recruited to the centrosome along with Parkin 
[60]. Although ubiquitin modified CDCrel-1 was detected in 
the absence of transfected parkin, levels increased with 
expressed Parkin and CDCrel-1 was found to be degraded in 
pulse-chase assays [38]. Originally thought to be associated 
with synaptic vesicles, more recent evidence suggests that 
only a small fraction of CDCrel-1 is found in synaptic 
vesicles [61]. Although the role of CDCrel-1 in Parkinson’s 
disease has not yet been clarified, a number of possibilities 
that lead to inhibition of dopamine release have been 
proposed [38]. Observations of CDCrel-1 null mice revealed 
no significant disruption of brain function, suggesting that 
other septins likely compensated for loss of CDCrel-1 [62]. 
Another septin, SEPT5_v2a is a close homolog of CDCrel-1 
[63] and accumulated in 3 of the 4 ARJP brains examined 
[63]. 
 Pael-R, a toxic protein when over-expressed (discussed 
above), was also reported to accumulate in the endoplasmic 
reticulum during unfolded protein stress. The up-regulation 
of BiP (marker gene for unfolded protein response), 
confirmed that the cells were responding to unfolded protein 
stress. Six hours after proteasome inhibition, Pael-R was 
found in the endoplasmic reticulum; after 16 hours, Pael-R 
was located within aggresome-like inclusions at juxtanuclear 
sites [49].  
 Although Parkin may be found in aggresomes/Lewy 
bodies, it may be sequestered for different purposes. 
Proteasomal inhibition resulted in aggresomal sequestration 
of wild type Parkin presumably to aide in the degradation of 
unfolded proteins [64], However, several Parkin mutations, 
e.g. R256C, R275W, C289G, and C418R which reduce 
Parkin solubility are relocated from cytoplasm to 
aggresomes, presumably to degrade the insoluble Parkin [21, 
28, 65, 66].  
Mechanics of Aggresome Formation and Microtubules 
 Proteins destined for aggresomal degradation are actively 
transported along microtubules to the centrosome as are 
components of the UPS, e.g. ubiquitin, ubiquitin conjugating 
enzymes, proteasomal constituents, certain chaperones, and 
mitochondria. These components are then organized into an 
aggresome (reviewed in Olanow et al. (2004)) [45]. When 
the cellular proteosomal system is inhibited, Parkin is 
recruited to the centrosome; removal of proteosomal 
inhibition reverses the centrosomal binding and Parkin is 
dispersed [60, 67]. This is accomplished by histone 
deacetylase 6 (HDAC6) which appears to sense proteosomal 
efficiency [67]. Generally, ubiquitinated proteins that are 
transported to the centrosome bind to the C-terminal ZnF-
IBP motif of HDAC6 (discussed in Jiang et al. (2008)) [67]. 
Parkin however, binds to two other regions in HDAC6, DD1 
and DD2. The interaction between Parkin and HDAC6 is 
direct and not mediated by microtubules. Recruitment of 
Parkin to the centrosome was shown to be dependent on 
HDAC6/dynein motor protein binding, and dispersal 
dependent on HDAC6 switching to the kinesin 1 protein 
(KIF5) [67]. HDAC6 deacetylates tubulin, and although 
apparently not acting directly on Parkin, the tubulin 
deacetylase activity of HDAC6 is required for Parkin 
recruitment to and dispersal from the centrosome [67].  
 Considering the importance of microtubules for 
centrosomal recruitment of Parkin and substrate proteins, it 
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comes as no surprise that Parkin, as a top level manager in 
the cell’s Sanitation Department takes some responsibility 
for microtubule quality control and stabilization. 
Microtubules are formed from /  tubulin heterodimers, and 
monomer levels of  and  tubulin are closely regulated so 
that neither is in excess. In addition, correct folding of 
tubulin is a complex process that results in a high level of 
misfolded tubulin (discussed in Ren et al. (2003)) [68].  
Parkin co-immunoprecipitated with  or -tubulin monomers 
in HEK293 cells and in rat brain lysates, and with /  
tubulin heterodimers in rat brain lysates [68]. A third type of 
tubulin, -tubulin, co-localized with Parkin in Lewy bodies 
(reviewed in Olanow et al. (2004) [45]
,
 McNaught et al. 
(2002)) [69]
 
.  
 Parkin interacts with microtubules, binding very tightly 
even in the presence of 3.8 M NaCl or 0.5 M urea and acting 
as a MAP (microtubule-associated protein [70]). 
Microtubules were stabilized when bound to wild type 
Parkin in the presence of the microtubule de-polymerizing 
agent, colchicine [70]. Parkin alone protected against the 
microtubule de-polymerizing PD toxin, rotenone, as shown 
by loss of protection in -lymphocyte and fibroblast cell 
cultures derived from PD patients carrying Parkin mutations 
[71]. Parkin/microtubule interactions that function to 
stabilize microtubules do not appear to interfere with E3 
ligase activity [68].  
V. OTHER PARKIN-PROTEIN INTERACTIONS 
 Parkin interacts with a number of proteins that are not 
substrates for ubiquitination and are not targeted for 
degradation although they may be involved indirectly in 
protein quality control. These proteins may share properties 
with those in categories described above, or they may have 
some other important feature, i.e. location, function or, in the 
case of an enzyme, activity, that warrants a class of its own. 
A number of interacting proteins form multi-member protein 
complexes with Parkin. According to Marin and Ferrus 
(2002) there are six unrelated types of proteins or protein 
complexes with E3 ligase activity [14]. These proteins may 
have E3 ligase activity by themselves or as members of 
multi-protein complexes; the SCF, APC and VCB-like 
complexes are well characterized examples (reviewed in 
Tyers and Williams (1999)) [72]. In these complexes, RING 
structures play a central role both in complex formation and 
in E3 ubiquitination activity. In some cases the E3 ligase 
activity of Parkin may be self-contained, i.e. no proteins 
other than ubiquitin, E1 and E2 are required for E3 ligase 
activity [27, 39], in other cases Parkin may function as a part 
of a multi-protein complex. We will discuss these interacting 
proteins in this section.  
 BAG5, a component of Lewy bodies in sporadic PD 
interacts with hsp70 and with Parkin [73]. BAG5 inhibits the 
chaperone activity of hsp70 and, independent of hsp70, the 
E3 ligase activity of Parkin. Co-transfection of Parkin and 
hsp70 prior to proteosomal inhibition reduced the 
recruitment of Parkin to the centrosome, presumably because 
chaperone activity of hsp70 successfully refolds proteins and 
they do not require degradation. However, triple 
transfections of Parkin, hsp70, and BAG5 prior to 
proteasomal inhibition nullified the effect of hsp70, and 
Parkin was recruited to the centrosome [73]. BAG5 can 
therefore promote Parkin sequestration and enhance Lewy 
body formation. BAG5 also inhibits the decrease in cell 
death effected by Parkin when the ubiquitin proteosomal 
system is overwhelmed. BAG5 is expressed in dopaminergic 
neurons in the substantia nigra, and mRNA and protein 
levels are increased in response to neuronal injury. 
Expression of BAG5 promotes neurodegeneration in 
dopaminergic cells of the substantia nigra when expressed in 
rat brain [73].  
 Similar to ubiquitin, small ubiquitin-like modifiers 
known as SUMO can be attached to proteins as a signal. 
Also similar to ubiquitin, SUMO molecules are attached to 
their target protein by an E3 ligase specific for SUMO. 
RanBP2 is a member of a small ubiquitin-like modifier 
(SUMO) E3 ligase family and a substrate of Parkin. 
Carboxy-terminal glycine residues in the SUMO proteins are 
linked to lysines in the target protein via isopeptide bonds. A 
complex chain of events involving Parkin, Ran BP2, 
HDAC4, histones, chromatin condensation, and transcription 
allows Parkin to indirectly control transcription. RanBP2, is 
a 356 kDa component of the nuclear pore complex, in 
particular of the nuclear pore cytoplasmic filaments where 
disassembly of export complexes occurs [74], and RanBP2 
binds to both Parkin and HDAC4 [75]. Levels of RanBP2 
are controlled by Parkin ubiquitination and proteasome 
degradation. RanBP2 in turn regulates levels of HDAC4 by 
sumoylation [75]. HDAC4 is a Class II deacetylase and 
therefore shuttles between the cytoplasm and the nucleus 
through the nuclear pore complex (discussed in detail in Um 
et al. (2006)) [75]. HDACs deacetylate histones thereby 
promoting chromatin condensation and repressing 
transcription. Through control of RanBP2 levels it is 
possible for Parkin to indirectly control transcription.  
 It was also found that Parkin binds specifically to 
SUMO-1 (there are three classes of SUMOs, SUMO-1, -2, 
and -3), and although the binding is not a covalent 
modification it is sufficient to promote Parkin auto-
ubiquitination and to transport Parkin from the cytoplasm to 
the nucleus [76]. Determining a mechanism for Parkin 
transport to the nucleus was an important finding considering 
the nuclear location of some Parkin substrates, e.g., SIM2 
[46], Cyclin E [77], and poly-(Q)-expanded huntingtin [9].  
 Parkin associates with proliferating cell nuclear antigen, 
PCNA, a protein that coordinates DNA repair [78]. The 
parkin gene is located in a genomically unstable region 
(detailed in Kao (2009)) [78], and as a result, Parkin 
mutations, deletions and duplications are found in 
carcinomas of breast, lung, ovary and liver. Experiments 
utilizing SH-SY5Y cells stably transfected with control 
vector, wild type or mutated Parkin were irradiated [78] and 
expression of wild type Parkin was found to increase the 
number of surviving colonies. PCNA was implicated as a 
Parkin binding protein by co-immunoprecipitation [78]. 
PCNA interactions are mediated by a PCNA interacting 
peptide domain (PIP) and Parkin contains an imperfect, but 
functional, PIP domain in RING1 [78]. Parkin did not 
ubiquitinate PCNA in this study and several possible 
functions resulting from the Parkin/PCNA interaction were 
suggested, all of which would depend on how Parkin 
affected the binding properties of the PCNA complex [78]. It 
was found that DNA damage relocated Parkin to the nucleus 
[79].  
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 Cyclin E is a regulatory subunit of cyclin-dependent 
kinase 2 protein that is highly expressed in adult brain 
neurons. Parkin forms a multi-protein complex with proteins, 
hSel-10 and Cullin-1, that, along with the E2, UbcH7, 
ubiquitinates Cyclin E. Increased levels of Cyclin E result in 
neuronal cell apoptosis in cells exposed to excitotoxic stress. 
hSel-10 contains the F-box and the WD repeat, common 
protein binding domains in E3 ubiquitin ligase complexes, 
although only the F-box domain is required to form the 
Parkin complex (detailed in Starpoli et al. (2003)) [77]. hSel-
10 is an intermediate in the Parkin/Cullin-1 association since 
Parkin fails to bind Cullin-1 in the absence of hSel-10. An 
ARJP RING1 mutation, T240R, inhibits interaction of 
Parkin with hSel-10 and consequently Cullin-1. As a Parkin 
substrate, Cyclin E accumulates in the absence of Parkin. 
Regulation of Cyclin E by Parkin, plays a role in glutamate 
excitotoxicity as Parkin was shown to protect midbrain 
dopamine neuron cultures from kainate excitotoxity [77]. 
 Interestingly, the three proteins involved in autosomal 
recessive PD pathogenesis, PINK1, DJ-1, and Parkin, form a 
three protein complex that functions to promote degradation 
of unfolded proteins via an E3 ligase activity that is more 
robust than that of Parkin alone [80]. ARJP may result from 
mutations in any one of these three genes. Parkin, PINK1, 
and DJ-1 interact via distinct domains and form a 200 kDa 
complex [80]. Perhaps the most significant aspect of this 
study is that participation in this complex appears to 
completely re-direct the function of PINK1 and DJ-1. Alone, 
both are involved with mitochondria. Although PINK1 alone 
is found in the mitochondria (and Parkin has been shown to 
alleviate aberrant mitochondrial morphology that occurs 
when PINK1 is absent or mutated [81]), it was shown that a 
55kDa PINK1 fragment co-precipitated with Parkin. The 
complete PINK1 protein localized to the mitochondria 
whereas the 55kDa fragment that binds to Parkin was mainly 
in the cytosol [80].  
 During cell division, mitochondria are fragmented into 
hundreds of spherical vesicles to allow partitioning of 
mitochondrial fragments into the two daughter cells [82]. 
This process of mitochondrial division and fusion also 
happens during synapse formation in hippocampal neurons 
where mitochondria are recruited into neural protusions [83]. 
PINK1 is required for the normal transition between 
mitochondrial division and fusion [84]. From observation of 
DJ-1 knockout mice, the DJ-1 protein likely functions in the 
removal of hydrogen peroxide from mitochondria [85]. 
However, when combined into a PINK1, DJ-1, and Parkin 
complex, the assembly functions to degrade unfolded 
proteins [80].  
 The function of another multi-protein complex, CHIP, 
hsp70, and Parkin determines the fate of unfolded proteins. 
In this complex, Parkin appears to play the role of committee 
chair, recruiting committee members to make and carry out 
protein triage decisions. One committee member, hsp70, is a 
chaperone and functions in ATPase-dependent cycles of 
binding and release from small hydrophobic regions of 
misfolded proteins (reviewed in Bukau and Horwich (1998) 
[86]). Upon release, the protein may refold into its proper 
native structure, may bind hsp70 again, may aggregate, or 
may bind to other chaperones or preoteases. Imai et al. 
(2002) [87] report that hsp70 transiently binds to the 
complex substrate, in this case unfolded Pael-R, while, at the 
same time inhibiting Parkin E3 ligase activity. This prevents 
two conflicting processes, hsp70-directed refolding into 
proper native structure and ubiquitination prior to 
degradation, from happening simultaneously. 
 CHIP (carboxyl terminus of the Hsc-70 interacting 
protein) functions as a triage protein, directing proteins 
either for chaperone refolding or for proteasome degradation 
[88, 89]. Specifically, CHIP inhibits hsp70 substrate binding 
and refolding activities [90, 91]. In the CHIP, hsp70, Parkin, 
Pael-R complex, CHIP dissociates hsp70 from Pael-R, and 
thereby relieves Parkin E3 ligase inhibition so that Pael-R is 
ubiquitinated. This is accomplished through a higher binding 
affinity between Parkin and CHIP than between Parkin and 
hsp70 [87]. Consistent with the order of activity described 
above, i.e., binding of chaperone, followed by triage and 
ubiquitination, SH-SY5Y cells showed a transient increase in 
Pael-R-hsp70 association at 6 hours after induction of 
unfolded protein stress followed by a marked decrease in 
association at 24 hours [87].  
 Both CHIP and the chaperone hsp70 bind to wild type 
Parkin as well as any Parkin mutants containing an intact 
RING1 [87]. Interestingly, CHIP contains a U box (with 
similarity to yeast protein UFD2) that may, in vivo, act as an 
E4, elongating ubiquitin chains and directing unfolded 
proteins for degradation by the UPS (Koegl et al. (1999) [44] 
and discussed above). However, with proteasomal inhibition, 
e.g. in SH-SY5Y cells treated with the proteosome inhibitor 
lactacystin, CHIP, Pael-R and Parkin localized to 
aggresomal structures [87].  
 PDZ (postsynaptic density-95, disc large, zona 
occludens) domains are approximately 90 amino acids in 
length and interact with a specific short peptide sequence 
generally located at the C terminus of the ligand (reviewed in 
Sheng and Sala (2001)) [92]. The C-terminus of Parkin 
contains one of these specific short peptide sequences, 
(amino acids FDV) and has been found to interact with the 
PDZ protein, CASK [61]. CASK is a member of a large 
multi-protein complex that in rat brain, co-localized with 
Parkin within post synaptic densities and in the Triton X-
100-insoluble lipid raft membrane compartment [61]. CASK 
is not a substrate for Parkin ubiquitination. More likely 
CASK serves as a link to formation of a large multiprotein 
complex, especially as Parkin co-immunoprecipitates, but 
does not bind directly to members of the complex which 
includes the PDZ protein PSD-95, the NMDAR subunit 
NR2B, the calcium and calmodulin-dependent protein kinase 
II (CaMKII), and homer 1a. These proteins are implicated in 
NMDA activity at the post synaptic density [61].  
 More recently it was discovered that a small amount of 
Parkin associates with membranes regardless of whether the 
PDZ peptide sequence is intact [30]. Further, disruption or 
removal of the PDZ peptide sequence does not impair 
Parkin’s neuroprotective function following kainate 
treatment, suggesting that protection from excitotoxicity 
does not reside solely in the Parkin/CASK interaction [30]. 
 At least three E2 ligases bind to the Parkin RING2. These 
include UbcH8 [17, 38], UbcH7 [37] and the E2 ligase 
UbcH13 which dimerizes with Uev1a (UbcH13/Uev1a) and 
mediates Lys 63-linked ubiquitin chain formation thereby 
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targeting proteins to the aggresome rather than UPS for 
degradation [93-95]. 
VI. REGULATION OF PARKIN 
 Parkin catalytic activity is negatively regulated by hsp70 
in the CHIP, hsp70, Parkin complex as well as by BAG5 [73, 
87]. And Parkin E3 ligase activity is positively regulated by 
the three protein complex, PINK1, DJ-1 and Parkin [80]. 
 In another regulatory pathway, a chaperone-like protein, 
14-3-3  binds to Parkin, negatively regulating both substrate 
binding and Parkin E3 ubiquitin ligase activity [96]. 14-3-3  
binds to Parkin RING0 which contains the amino acid 
sequence RKDSPP (amino acid residues129-134), a typical 
binding motif for 14-3-3 proteins. -synuclein and Parkin 
compete for 14-3-3 , therefore an increase in -synuclein 
concentration relieves the inhibition on Parkin-substrate 
binding and E3 ligase activity. The authors suggest that 
under conditions of low -synuclein concentration, Parkin-
14-3-3  binding allows large quantities of inactive Parkin to 
be retained in the cell by inhibiting the self-ubiquitination 
and proteasomal degradation that is observed in cultured 
cells over-expressing Parkin. As levels of -synuclein rise 
and compete for 14-3-3  Parkin-substrate binding and 
ubiquitation activity would be restored [96]. 
 Parkin activity is also regulated by reversible 
phosphorylation. Phosphorylated Parkin shows decreased E3 
ligase activity suggesting that phophorylation down-
regulates ubiquitination [97]. In the presence of ER unfolded 
protein stress, phosphorylation is reduced and E3 ligase 
activity increased. Proteasomal inhibition also reduces 
Parkin phosphorylation, although not as much as unfolded 
protein stress. Reduction of phosphorylation is specific to 
proteosomal dysfunction and ER stress; oxidative stress did 
not alter Parkin phosphorylation levels [97]. 
 Parkin is constitutively phosphorylated although rapid 
turnover requires use of the phosphorylation inhibitor, 
okadaic acid, to identify phosphorylated Parkin [97]. Five 
serine phosphorylation sites, S101, S131, S136, S296. and 
S378 were identified and evidence of weakly phosphorylated 
threonine residues were also observed. These five serine 
residues are in the spacer between the Parkin Ubl and 
RING0 (S101, S131, S136); between RING1 and the IBR 
(S296); and between the IBR and RING2 (S378). Mutational 
analysis of the 5 serine sites confirmed that these were not 
the only sites phosphorylated in Parkin, and also that none of 
the 5 serine sites appeared to have a unique regulatory role 
[97]. Kinases likely involved in Parkin phosphorylation were 
identified as CK-1, PKA, and PKC.  
 S-nitrosylation can also regulate Parkin E3 ligase activity 
[98, 99]. Regulation is biphasic with activity increasing 
within a few hours of treatment with S-nitrocysteine and 
decreasing 12-24 hours later [99]. When SH-SY5Y cells 
over-expressing Parkin were incubated with S-
nitrosocysteine, S-nitrosothiol formed on Parkin [99]. By use 
of peptide mass fingerprinting, (Q-TOF) MS, five of seven 
Cys residues in RING1 and potentially five Cys residues in 
RING2-IBR were shown to have undergone S-nitrosylation 
modification [99]. Mutational analyses of cysteines in the 
IBR showed that no single mutation eliminated S-
nitrosylation, implying that multiple Cys residues are 
involved; quantitative analysis revealed that approximately 
three Cys residues per Parkin molecule are S-nitrosylated 
[98].  
 Interaction with SUMO-1 regulates both Parkin auto-
ubiquitination and Parkin localization to the nucleus [76]. 
Since Parkin also interacts with RanBP2, an E3 SUMO 
ligase, Um and Chung questioned whether Parkin might be a 
substrate of RanBP2. However, SUMO-1 is not covalently 
attached, and therefore Parkin is not a substrate of RanBP2 
[76]. 
 With regard to structure vs function, regulatory activity 
appears to be spread over most of the Parkin molecule. 
Several regulatory factors appear to interact with RING0, 
e.g., PINK1 [80], 14-3-3  [96] , and BAG5 [73]. Confirmed 
phosphorylation sites are spread from RING0 through the 
IBR, and nitrosylation occurs throughout the RBR region. 
VII. PARKIN-PROTEIN INTERACTIONS AND E3 
UBIQUITIN LIGASE ACTIVITY 
Parkin-Protein Interactions 
 Generally, Parkin binding sites were determined by 
immunoprecipitation of the Parkin substrate or interacting 
protein using various fragments of Parkin. Several studies 
used different Parkin domains, parts of domains, or 
combinations of domains in their binding assays, thereby 
making comparisons between reported Parkin/protein 
interaction sites difficult. Keeping this in mind, certain 
generalizations regarding Parkin-protein binding can be 
made.  
 One important observation is that Parkin-protein 
interaction sites are spread over the entire Parkin molecule 
(Table 1). RING2 appears important for many proteins, 
either as the single binding site, as a part of a larger binding 
site, or as an alternative binding site. RING2 alone appears 
sufficient for binding Synphilin 1 [48], Pael-R [49], and 
UbcH13 [95] SIM2 [46] and 4 [41] require the adjacent 
IBR in addition to RING2, and the entire RBR is needed for 
DJ-1 [80] and hSel-10 [77]. Some proteins interact with 
RBR domains other than RING2. PCNA binds to a fragment 
containing both RING1 and the IBR (although the two 
domains were not tested separately) [78]; and both CHIP and 
hsp70 bind to RING1. Several proteins bind to domains 
outside of the RBR. RING0 is an alternative site for tubulin 
[70] and HDAC6 binding [67]; BAG5 appears to be the only 
protein that interacts solely with RING0 [73]. Rpn10 appears 
to be the only protein discovered thus far that interacts only 
with the ubiquitin-like domain [40]; Sept5_v2a interacts with 
either the ubiquitin-like domain or RING1-IBR of the RBR 
region [63].  
E3 Ubiquitin Ligase Activity 
 A number of studies have suggested that requirements for 
binding are less stringent than are requirements for 
ubiquitination or degradation of Parkin substrates. There are 
some general “rule of thumb” guidelines involving mutations 
that can be useful in examining binding sites. For instance, if 
a mutation is known to change the conformation of a 
molecule and also affects binding properties, then the 
binding site may be dependent on the conformation of the 
molecule. If the binding site requires non-consecutive 
regions of the molecule, then likely the site requires a 
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Table 1. Parkin-Protein Binding Sites. Sites in Parkin which have been Shown to Associate with other Proteins 
Parkin Ubl 
(1-76) 
RING0 
(150-169) 
(196-215) 
RING1 
(238-293) 
IBR 
(332-377) 
RING2 
(418-449) 
PDZ 
 
Referencs 
synphilin 1 
Pael-R 
UbcH13 
    yes 
 
 [48] 
[49] 
[95] 
UbcH8   ?  yes  [38] 
UbcH7   yes yes ?  [37] 
CDCrel-1   yes +yes or yes  [38] 
Tubulin 
HDAC6 
 yes 
 
yes  yes  [70] 
[67] 
Cyclin E 
(hSel-10) 
WD 
repeat 
(not required) 
 yes 
F-box 
yes 
F-box 
yes 
F-box 
 [77] 
 
SIM2    yes +yes  [46] 
4    yes +yes  [41] 
Synaptotagmin XI  yes 
(204-238) 
yes 
(257-293) 
   [53] 
CHIP   yes (+ ?)    [87] 
hsp70   yes (+ ?)    [87] 
PCNA   yes +yes   [79] 
BAG5  yes     [73] 
RanBP2 yes (78- 170) yes     [75] 
Rpn10 yes      [40] 
PINK1  (93- 212) yes     [80] 
DJ-1   yes 
(217-465) 
+yes +yes  [80] 
CASK      yes [61] 
p38    yes (bait)    [51] 
Sept5_v2a yes or  yes +yes   [63] 
14-3-3   yes     [96] 
The Parkin domains, Ubl, RING0, RING1, IBR RING2 and the specific short peptide sequence that binds PDZ domains are listed in the top row of the table. The proteins that 
associate with Parkin are listed in the left hand column. An empty box under a particular parkin domain means that domain has not been implicated in binding to the protein listed in 
the left column. A “yes” indicates that the protein listed on the left binds to that particular Parkin domain. A “?” indicates that the data is unclear in regard to whether the protein binds 
to that parkin domain. For instance, RING1, although not required for UbcH8 binding to Parkin, may enhance the binding interaction. A “+ yes” indicates that this domain is required 
in addition to another domain. A “+ ?” means that another unidentified domain is also needed . “Or yes” indicates an alternative binding site. 
structure that pulls those disparate regions together. And 
finally, if a binding site is a small specific primary sequence 
of amino acids, then the tertiary structure is less likely to 
affect binding unless the site is obscured by the tertiary 
structure. In such cases a mutation may actually increase 
binding if it denatures that small region of the molecule, 
perhaps by disruption of zinc ion binding that stabilizes the 
obscuring structure. Examples include: i) synphilin-1 which 
maps to RING2. As expected, familial-PD mutations in 
RING1 appeared to have no effect on binding; however, 
those in RING2 and the IBR actually increased binding [48]. 
At this point it is unclear why binding would increase. 
Although the ARJP mutations T240R and R256C (in 
RING1) as well as the truncating mutation W453X either 
had no effect or actually increased binding, ubiquitination of 
synphilin-1 was adversely affected by all three of these 
mutations [48]. Interestingly, a later investigation of the 
effect of mutations on Parkin E3 ligase activity identified the 
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mutation T240R as belonging to a set of mutations (K161N, 
T240R, Q311X, T415N and P437L) that are considered 
“ligase dead” since they neither auto-ubiquitinate nor 
substrate ubiquitinate [26]. R256C belongs to a set (R256C, 
G328E, G430Q, C431F, and W453X) that auto-ubiquitinates 
but not substrate ubiquitinates [26]; ii) tubulin is bound, but 
not ubiquitinated, in the presence of Parkin mutations 
K161N in RING0, T240R in RING1, and C431A in RING2 
[68]. Again, these belong to the set of “ligase dead” 
mutations [26]; iii) binding and ubiquitination of Parkin 
substrates (CDCrel-1, p38 and -tubulin) or associated 
proteins (  tubulin, hsp70 and the 4 subunit of the 
proteosome) were tested with ten Parkin mutations A82E, 
K161N, K211N, R256C, G328E, R42P, R275W, C289G, 
C418R, and C441R [27]. The binding interactions between 
these proteins and mutant Parkin variants did not appear to 
vary significantly from that of wild type Parkin. However, 
utilizing a cell-free in vitro ubiquitination assay that 
measured Parkin auto-ubiquitination, only C418R and 
C441R (which disrupt zinc ion binding in RING2) inhibited 
ubiquitination. Since the assay involved Parkin auto-
ubiquitination we would expect mutations R256C and 
G328E (in the set of mutations that auto-ubiquitinate) to be 
unaffected; however, K161N was not “ligase dead” as might 
be expected.  
 It should be noted that there are many discrepancies in 
reports of substrate ubiquitination, some likely due to effects 
of other proteins in cell-based assays. And “in vitro” assays 
utilizing recombinant Parkin purified from reticulocytes may 
be affected by protein contaminants. This was discussed 
thoroughly in the Hampe et al. report [27].  
General vs Specific Ubiquitination in the Presence of 
Parkin 
 Although Parkin expression increased ubiquitination of 
- and -tubulin in HEK293 cells, the authors also showed 
data suggesting that exogenous expression of Parkin may 
enhance ubiquitination levels for many different proteins 
[68]. Certainly, there is little doubt that Parkin recognizes 
specific proteins for ubiquitin modification; however, it is 
possible that Parkin alone or as a component of a multi-
protein complex, perhaps with chaperone complex members, 
can recognize something more general such as exposed 
hydrophobic regions. Whether Parkin switches between a 
specific substrate to more general substrates, and if so, 
determining the mechanism for such a substrate switch, is an 
interesting question for possible exploration. Similarly, many 
questions remain regarding the circumstances under which a 
Parkin substrate is “chosen” for binding and/or 
ubiquitination,  
VIII. PREDICTED RING STRUCTURES 
Structure 
 The three RING domains (0, 1 and 2) of the Parkin 
protein were modeled using the I-TASSER program that 
generates structure predictions by first identifying templates 
(proteins with similar fold) for the query protein from the 
Protein Data Base (PDB) library. I-TASSER then assembles 
the fragments derived from the templates into full-length 
models using the parallel replica-exchange Monte Carlo 
simulations [100].  
 The models generated for each Parkin domain were 
analyzed to identify plausible locations of zinc ion binding 
sites based on sequence alignment and the position of zinc 
coordination sites in templates identified by threading 
algorithms. Zinc ions were added near the plausible binding 
sites and the structure was refined using the Gromacs 
molecular dynamics simulation package [101] for the 
purpose of refining the local structure of the backbone and 
side-chain atoms. The position of ligand residues in modeled 
structures of the three RING domains (0, 1, and 2) suggest 
that each domain can bind two zinc ions. We also modeled 
the Ubl and the IBR domain of Parkin. However, as our 
results are in agreement with the known structure of other 
ubiquitin conjugating proteins and with those presented 
earlier by Tomoo et al. (2008) [22] and Beasely et al. (2007) 
[17], we will not present our results here.  
Model of RING1 
 The fold of RING1 closely matches the RING finger 
domain of human UbcM4-interacting protein (PDB: 1WIM). 
The predicted structure of the RING1 domain (Fig. 2A) and 
the threading alignment with the identified template, suggest 
that RING1 adopts the classical zinc ligand spacing [12, 102, 
103] (Fig. 1B, 2B) and assumes a typical cross brace 
structure (Fig. 1C) with residues C238, C241, C260 and 
C263 as ligands in the first zinc co-ordination site and C253, 
H257, C289 and C293 present in the second site.  
Model of RING0 
 Our predicted structure for the RING0 domain is 
different from the previously proposed model. For example, 
a model for RING0 structure was proposed by Hristova. et 
al. consisting of two zinc binding sites containing (C4 and 
C3H) separated by a linker region (Fig. 1A). Because the 
linker region separating the zinc binding motifs is very large 
(26 amino acid) and because HOIL-1, the only other RBR 
protein to contain a zinc binding motif upstream of RING1, 
has only one zinc binding motif, Hristova et al. (2009) [19] 
proposed a model in which RING0 binds two zinc atoms in 
an independent and linear fashion rather than in a cross brace 
structure. However, a clear picture of the binding mode of 
zinc ions in the RING0 domain remained elusive.  
 Structure modeling of RING0 using the automated fold 
recognition procedure for RING0 did not identify any 
significant templates and therefore the model quality was 
low because the templates had diverse folds. Accordingly, 
the template proteins in the PDB library were filtered based 
on the presence of bound zinc ions and a linker region of at 
least 20 residues between the zinc coordination sites. The 
search resulted in identification of three DNAJ/hsp40 
cysteine rich domains (PDB: 1exk), with sequence 
conservation mainly at/or near ligand binding sites.  
 The overall topology of the predicted model for RING0 
(Fig. 3A and B) is based on the DNAJ/hsp40 homology and 
differs from that proposed by Hristova et al. (2009) [19] in 
that the two zinc binding sites are interleaved, with a V-
shaped extended -hairpin topology in the linker region, 
similar to the cysteine rich domain of DNAJ. The long linker 
apparently does not impair binding of zinc ligands. The rest 
of the domain contains only a limited amount of regular 
secondary structure. The first binding site consists of 
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Fig. (2). The predicted model of the RING1 domain using the I-TASSER algorithm. The model has a typical cross-brace structure and is in 
agreement with the previously suggested structure for Parkin RING1. The template identification was conducted using LOMETS, a meta-
threading server appoach with 9 third-party threading programs installed locally [111]. Multiple templates were collected from the top-
ranking alignments in each of the 9 individual programs in LOMETS. A composite force field, consisting of the inherent knowledge-based 
potential and the spatial restraints collected from the multiple template structures, is then used for guiding the fragment assembly Monte Carlo 
simulations. The final models were selected based on the frequency of occurrence of the conformation appearing during the I-TASSER 
reassembly simulations (or the cluster size), identified by SPICKER [112]. Finally, full-atomic models are built by REMO [113] by 
optimizing the hydrogen-bonding network. B) The spacing of zinc site ligands in RING and LIM structures as described by Lovering et al. 
[12] and Freemont [103]. The ligands are numbered from one to eight in the top row and the intervening amino acid residues are depicted as 
“X”. The ligand spacing and location of the His residue is nearly the same in the two RING descriptions. The LIM structure is different in 
ligand spacing and also in location of the His residue. 
Ligands one (Cys 150), two (Cys 154), seven (C212) and 
eight (H215), while the second is composed of Ligands 3-6 
(C166, C169, C196, and C201). While the predicted model 
requires experimental validation, it provides the first 
plausible three dimensional model for zinc binding in 
RING0.  
Model of RING2 
 A current model for RING2 structure is based on zinc ion 
ligand residues C418, C421, C431, H433, C436, C441, and 
C449 identified by Morett and Bork (1999) [104]. The model 
fits the classical ligand spacing [12, 102, 103, 105] (Fig. 2B), 
however spatial limitations prevent it from easily fitting into 
a cross-brace structure (Fig. 1C). In the Morett and Bork 
model, C418, C421, C431, H433 coordinate to the first zinc 
ion, but Capilli et al. (2004) showed that the RING2 domain 
of HHARI, a protein that shares both the RBR domain 
structure and the E3 ligase function of RING2 with Parkin, 
did not form a cross brace structure and binds only one zinc 
ion [18]. By analogy it was suggested that the RING2 
domain of Parkin may also bind just one zinc atom (Fig. 
4A). However, this contrasts with the zinc titration analysis 
that suggested that Parkin can bind a total of eight zinc ions, 
two each for RING0, RING1, IBR, and RING2 [19].  
 While analyzing the predicted models of RING2 and the 
alignment with identified template proteins (RING2 of 
HHARI and IBR domain of RING finger domain of protein 
31), we found that another conformation was possible for 
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Fig. (3). A) Our predicted structural model of the RING0 domain. The ligand residues shown in yellow (C150, C154, C212, and H215) 
represent the first zinc ion binding site; those in orange (C166, C169, C196, C201), the second binding site. B) A line drawing of our 
predicted structure shows the two interleaved zinc ion binding sites. Ligands one and two pair with seven and eight to form the first zinc 
binding site and the four internal Cys residues form the second zinc site. This is different than the RING0 structure predicted by Hristova et 
al. [19] where the first four Cys ligands form the first zinc site and the last three Cys plus the His residue form the second zinc binding site. 
Parkin RING2 that uses a different set of ligands to 
accommodate two zinc ions. This model suggests that C418, 
C421, C436 and C441 coordinate to the first zinc ion while 
C446, C449, C457 and H461 coordinate to the second zinc 
ion (Fig. 4B, 4C). The zinc coordination sites in the 
predicted model are similar to the IBR domain of RING 
finger protein 31, which also binds two zinc ions. With 
regard to spacing, the previous model of RING2 follows the 
Lovering and Freemont RING spacing, except for the 
presence of 4 rather than 2 amino acids between ligand 5 and 
6 (Fig. 2B). Our predicted structure follows the Lovering and 
Freemont RING spacing except there are 4 instead of 2 
amino acid residues between ligand 4 and 5, and 3 rather 
than 2 residues between ligand 7 and 8 (Fig. 4C). A major 
point of difference is that in our predicted structure, the 
RING2 domain boundary, defined as being 4 residues before 
the first Cys and 6 residues after the last ligand (a histidine 
rather than cysteine in our predicted structure) is followed by 
only 4 amino acid residues rather than the 6 residues, as 
defined by Freemont [103]. The predicted RING2 structure 
does not form the classical cross brace structure and the last 
amino acid involved in zinc binding is His461 (Fig. 4B). 
Therefore our predicted structure varies in spacing, in the 
RING domain boundary, and also in location of the histidine. 
Wong et al. (2007) [21] had earlier proposed a similar first 
zinc ion ligand binding site (C418, C421, C436 and C441) 
for RING2 based on homology modeling.  
 Our RING2 structural model can explain several 
previously puzzling observations about Parkin. One is the 
number of zinc ions bound by Parkin,. Our model predicts 
two for RING2 for a total of eight in full length Parkin as 
demonstrated by Hristova et al. (2009) [19]. Another is the 
observed instability of Parkin C-terminal deletions and 
chimeric Parkin-HHARI proteins [29, 30]. In our predicted 
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Fig. (4). A) The previous RING2 model based on the Morett and Bork (1999) selection of ligands [104]. The last four Cys ligands are 
constrained in their ability to form a zinc ion binding site and it was suggested that Parkin RING2 had only one bound zinc ion. However, 
experimental evidence suggested that Parkin RING2 binds two zinc ions [19]. B) Our newly predicted structural model explains how two zinc 
ions may be bound by RING2. C) Our predicted model for the RING2 domain with ligand residues in the zinc binding sites shown in orange 
(first binding site) and yellow (second binding site).  
RING2 structure the deletion resulting from the W453X 
mutation would delete the final two ligands, C457 and H461 
of the second zinc binding domain, explaining why this 
mutant spontaneously adopted an unfolded conformation 
[29]. Further, any C-terminal deletion greater than three 
amino acids resulted in the loss of Parkin solubility [29]. 
While H461 is the last ligand and fifth residue from the C-
terminal, the importance of W462 in Parkin has remained 
largely unknown. The role of the highly conserved 
tryptophan residues in RING structures, e.g. Parkin W453 
and W462, have been thought to be important for making 
interactions with other proteins, however the new insight 
into the metal-ion-recognition property of the indole ring of 
tryptophan suggests that the aromatic rings of these residues 
can form non-covalent interactions with zinc ions to provide 
rigidity to the RING structure and/or cause conformational 
changes leading to binding of zinc ions [106]. Therefore, as 
shown by Winkelhofer et al. (2003) [29] the last three 
residues, F463, D464, and V465, are the only dispensable C-
terminal amino acids in Parkin RING2.  
 In contrast to Parkin, HHARI tolerated C-terminal 
deletions [30]. To address this difference, chimeras of the 
two proteins were prepared in which C-terminal fragments of 
HHARI from residues 376, 379 or 395 onwards, were 
substituted for Parkin residues 449 or 453 onwards. The 
chimeras were assayed for stability in situ [30]. In all of the 
chimeric proteins, the final two putative zinc ligands (C457 
and H461) in our predictd RING2 model were substituted by 
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amino acids G, Y, H, W, K or D. In one case, a His residue 
replaced the C457 ligand, however this construct was still 
missing the zinc binding ligand at position 461. All of the 
chimeras proved to be unstable, supporting the hypothesis 
that Parkin RING2 contains two zinc binding sites, and, as 
predicted by the model, both are important for Parkin 
stability. 
 Our RING2 model also explains the unexpected result 
regarding the behavior of the C431A mutation in an 
ambitious study in which the Parkin cysteines were 
individually mutated to determine which ones affected 
Parkin solubility [21]. The C431A mutation remained 
soluble, which was puzzling as all other cysteine mutants 
resulted in insoluble Parkin. Although C431 is considered as 
a ligand in the first zinc binding site in the Morett and Bork 
RING2 structure, C431 is not a ligand in either of the two 
zinc binding sites of our predicted RING2 structure 
(Compare Fig. 4A with 4B). This provides further support 
for the predicted RING2 structure.  
 Another previously puzzling observation came from 
Hampe et al. (2006) [27] in which mutation of either C418 
or C441 in Parkin resulted in loss of autoubiquitination 
activity. Using the Morett and Bork (1999) ligand selection, 
C418 was a part of the first zinc binding site, whereas C441 
was in the second zinc binding site. If Parkin RING2 was 
similar to HHARI RING2, we would expect the second zinc 
site to be unimportant for catalytic activity and hence the 
mutation of C441 would retain activity. However, that is not 
the result obtained by Hampe et al. (2006). Using our 
predicted RING2 structure, ligand C441 is a member of the 
first zinc binding site and therefore, like C418, should inhibit 
Parkin ubiquitination activity when mutated. This is 
consistent with the Hampe et al. (2006) [27] results.  
 From observations of zinc binding sites in RING 
domains discussed in Kentsis et al. [107], it appeared that 
zinc binding sites may show negative cooperativity in zinc 
binding, i.e. binding of zinc in one binding site reduces the 
affinity for binding of zinc to a second site. Considering that 
the new conformational structure proposed for the RING2 
domain would explain several earlier observations, we 
hypothesize that Parkin assumes this conformation, at least 
part of the time. Whether or not the two zinc binding sites 
remain occupied continually, or whether Parkin can function 
(or remain soluble) with just one zinc ion bound remains to 
be determined. Indeed, domains with just one bound zinc ion 
have been shown to self-assemble into stable multi-RING 
structures that enhance the function of individual RING 
domains [107]. Based on these and related observations 
[108-110], an attractive possibility is that, in response to 
changing physiological conditions, a transition between 
bound and unbound zinc ions at one of the two zinc binding 
sites of Parkin RING2 promotes a change in local structure 
that acts as a mechanical switch, providing a mechanism 
whereby Parkin-protein association may be altered resulting 
in a change in function. Although an interesting hypothesis, 
a significant amount of work remains to be done with Parkin 
RING2 in exploring that hypothesis.  
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ABBREVIATIONS 
PD = for Parkinson’s disease 
DJ-1 = is a cDNA clone identified from a HeLa cell 
library by yeast 2-hybrid screening for 
proteins interacting with C-myc. It encodes a 
189 amino acid protein and is also known as 
PARK7 
ARJP = for Autosomal Recessive Juvenile Parkinson’s 
disease 
hsp70 = for a family of 70 kilodalton heat shock 
proteins 
HHARI = for human homolog of the Drosophila 
Adriadne gene 
RING = for cysteine-rich domain of a Really 
Interesting New Gene 
IBR = for the Parkin domain In Between RINGs 
RBR = for the three Parkin domains, RING1, IBR, 
and RING2 
EDTA = for Ethylenediamine Tetraacetic acid 
Ubl = for Parkin ubiquitin-like domain 
UPS = for ubiquitin proteasome system 
ER = for endoplasmic reticulum 
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